Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Euronext N.V.. (11/11/15). "Press Release: EnterNext Welcomes Curetis on Euronext Amsterdam and Euronext Brussels. Curetis Raises € 40 Million, Reaches Market Capitalization of € 151 Million". Amsterdam & Brussels.

Organisation Organisation Curetis N.V.
  Group Curetis (Group)
Products Product investment banking
  Product 2 Unyvero molecular diagnostics platform
Index term Index term Curetis–SEVERAL: investment, 201510–201511 IPO €40m+€4.3m w 4m+431k new shares at €10/share at Euronext Amsterdam + Brussels
Persons Person Schacht, Oliver (Curetis 201012– CEO before Epigenomics CFO)
  Person 2 Ganyushin, Albert (Euronext 201511 Head of International Listings)
     


EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs, today celebrated the listing of Curetis N.V. (the “Company” and, together with Curetis AG, “Curetis”), a developer of next-level molecular diagnostic solutions. Curetis listed on Euronext Amsterdam and Euronext Brussels (ticker code: CURE).

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions offered by Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in a few hours, a process that today can take up to days or even weeks with other techniques. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering countries across Europe, the Middle East and Asia.

The issue price of Curetis was set at € 10.00 per share. Market capitalization was € 151 million on the day of listing. The offering raised € 40 million altogether.

Oliver Schacht, CEO of Curetis said: “The IPO is a major milestone in Curetis´ corporate history and we are proud to join the group of renowned healthcare companies listed on Euronext. The proceeds of the transaction will mainly be used to expand the commercialization of our Unyvero Platform and to expand our product portfolio to address additional infectious diseases.”

Maurice van Tilburg, CEO of Euronext Amsterdam said: “We’re delighted to welcome Curetis today as part of its IPO and dual-listing on Euronext Amsterdam and Brussels. The dual-listing gives the company optimal visibility and exposure in both respective markets. The diversity of investors and combined liquidity in both markets offer Curetis strong access to capital which will help execute its strategy and support further development.”

Vincent van Dessel, CEO of Euronext Brussels: “We are happy to partner with Curetis as it enters in a new phase of its development. The company now benefits from strong financing solutions on Europe’s most active market for life sciences. The unique offering of multiple listing venues across our markets will help Curetis to create optimal conditions to enhance its visibility and liquidity as public traded stock.”

Albert Ganyushin, Head of International Listings of Euronext added: “Curetis’ transaction is the second German company completing an IPO and the fourth international life sciences IPO on our markets recently and is a testament to the strength, resilience and growing international profile of our life science franchise. Including Curetis, Euronext has listed 15 IPOs of European life science companies since the start of 2015. We are delighted, especially considering the market volatility, that the potential of the diagnostic solutions developed and commercialized by Curetis has been recognized by the public market investors. This transaction demonstrates the capacity of Euronext markets to finance growth of European life science companies and the strength of our internationally established broker community focused on serving the European healthcare industry.”

To mark the listing, Curetis sounded the gong in Amsterdam to open the financial market.

   
Record changed: 2017-04-02

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Curetis (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px